Anixa Biosciences Secures Japanese Patent for Breast Cancer Vaccine Technology
Biotechnology company, Anixa Biosciences (Nasdaq: ANIX), has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for a patent application for its breast cancer vaccine technology. Anixa is developing a vaccine that activates the immune system against retired proteins to provide preemptive immune protection against emerging breast tumors. The vaccine is being evaluated in a Phase 1 clinical trial at Cleveland Clinic.
Anixa’s Chairman and CEO Dr. Amit Kumar, commented, “This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geographic region, beyond the U.S. and European patents previously awarded. As the exclusive worldwide licensee of the technology, we value the additional protection this patent provides as we continue clinical development.”
In 2023, nearly 300,000 new cases of invasive breast cancer were diagnosed in women, and approximately 2,800 new cases in men. The average age of women diagnosed with breast cancer is 62 years.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
